Patents Assigned to Viking Therapeutics, Inc.
  • Use of thyroid beta-agonists
    Patent number: 11951114
    Abstract: Methods useful for treating X-linked adrenoleukodystrophy are provided.
    Type: Grant
    Filed: May 6, 2022
    Date of Patent: April 9, 2024
    Assignees: Viking Therapeutics, Inc., Metabasis Therapeutics, Inc.
    Inventors: Brian Lian, Rochelle Hanley, Misha Dinerman, Mark Erion, Serge Boyer, Hongjian Jiang
  • Crystalline forms and methods of producing crystalline forms of a compound
    Patent number: 11787828
    Abstract: Disclosed herein are methods of crystallizing the compound of Formula I, as well as crystalline forms thereof. Crystalline forms of Formula I disclosed include the TBME solvate crystalline form, toluene solvate crystalline form, ethanol solvate crystalline form, THF solvate crystalline form, EtOAc solvate crystalline form, acetone solvate crystalline form and crystalline Form C.
    Type: Grant
    Filed: March 18, 2019
    Date of Patent: October 17, 2023
    Assignee: Viking Therapeutics, Inc.
    Inventors: Brian Lian, Hiroko Masamune, Geoffrey Barker
  • Compositions and methods for the treatment of metabolic and liver disorders
    Patent number: 11744873
    Abstract: Disclosed herein are small molecule GIP/GLP-1 dual receptor agonist compositions, pharmaceutical compositions, the use and preparation thereof.
    Type: Grant
    Filed: November 18, 2022
    Date of Patent: September 5, 2023
    Assignee: Viking Therapeutics, Inc.
    Inventors: Brian Lian, Geoffrey E. Barker, Maureen Barnes, Kader Yagiz, Erland Stevens
  • Compositions for the treatment of fibrosis
    Patent number: 11707472
    Abstract: The present disclosure is directed to methods of treating fibrotic conditions by administration of TR? agonists. The disclosure provides methods wherein the abnormal deposition of extracellular matrix components, such as collagen, keratin, or elastin, is reduced, either through interaction of TR? agonists with TGF-?-dependent inflammatory pathways, or by other mechanisms, thereby ameliorating fibrotic symptoms.
    Type: Grant
    Filed: June 4, 2018
    Date of Patent: July 25, 2023
    Assignee: Viking Therapeutics, Inc.
    Inventors: Brian Lian, Hiroko Masamune, Geoffrey E. Barker
  • Use of thyroid beta-agonists
    Patent number: 11351183
    Abstract: Methods useful for treating X-linked adrenoleukodystrophy are provided.
    Type: Grant
    Filed: April 24, 2017
    Date of Patent: June 7, 2022
    Assignees: Viking Therapeutics, Inc., Metabasis Therapeutics, Inc.
    Inventors: Brian Lian, Rochelle Hanley, Misha Dinerman, Mark Erion, Serge Boyer, Hongjian Jiang
  • Method of treating glycogen storage disease
    Patent number: 11202789
    Abstract: The present disclosure provides methods and compositions for the treatment of hepatic symptoms of glycogen storage diseases through the administration of thyroid hormone receptor agonists. The methods and compositions provided herein are useful in the treatment of hyperlipidemia, hypercholesterolemia, hepatic steatosis, cardiomegaly, hepatomegaly, hepatic fibrosis, and cirrhosis associated with glycogen storage diseases (GSD) and defects of glycogen metabolism. Said compounds may also be useful in the prevention of GSD-related hepatocellular adenoma and hepatocellular carcinoma.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: December 21, 2021
    Assignee: Viking Therapeutics, Inc.
    Inventor: Brian Lian
  • METHOD OF TREATING GLYCOGEN STORAGE DISEASE
    Publication number: 20190343850
    Abstract: The present disclosure provides methods and compositions for the treatment of hepatic symptoms of glycogen storage diseases through the administration of thyroid hormone receptor agonists. The methods and compositions provided herein are useful in the treatment of hyperlipidemia, hypercholesterolemia, hepatic steatosis, cardiomegaly, hepatomegaly, hepatic fibrosis, and cirrhosis associated with glycogen storage diseases (GSD) and defects of glycogen metabolism. Said compounds may also be useful in the prevention of GSD-related hepatocellular adenoma and hepatocellular carcinoma.
    Type: Application
    Filed: November 17, 2017
    Publication date: November 14, 2019
    Applicant: Viking Therapeutics, Inc.
    Inventor: Brian Lian